Researchers find tirzepatide more effective than semaglutide for weight loss in a 72-week trial, with significant reductions ...

A new study has pitted Wegovy and Zepbound head-to-head in their ability to treat obesity. Published in The New England Journal of Medicine on May 11, the study attempted to analyze the comparative ...

Tirzepatide (Zepbound) led to more weight loss than semaglutide (Wegovy) in a clinical trial funded by Eli Lilly.

Drugmakers are offering the blockbuster medications at steep discounts to people willing to pay out of pocket.

Cigna will cap out-of-pocket costs at $200 per month for patients using the weight-loss drugs Wegovy and Zepbound through an ...

Novo Nordisk will sell a less expensive one-month supply of Wegovy for patients who previously took compounded versions of ...

Cigna's Evernorth is rolling out a new pharmacy benefit management program that caps members' monthly cost for key GLP-1 ...

The new weight-loss option will cut what the plan sponsors pay as well as what the patients pay, Cigna’s PBM Evernorth says.

Eli Lilly & Co. (LLY) shares have come under significant pressure in late May following a pivotal decision by CVS Health's ...

Researchers are beginning to wonder if blockbuster drugs like Wegovy, Ozempic and Zepbound could play a role in preventing ...

True or False: Pooled trial data showed that rheumatoid arthritis patients taking tofacitinib (Xeljanz) were less likely to ...

The price of weight loss drugs is falling. Wegovy and Zepbound, which both sell for a list price of more than $1,000 a month, have long been out of reach for people without insurance or whose ...